Targeting Tumor Stroma
Boehringer Ingelheim’s research approach in stromal biology may lead to new medicines that will change the face of cancer and give new hope to patients
Search
Boehringer Ingelheim appoints new Regional Managing Director
Boehringer Ingelheim appoints new Regional Managing Director
Teaching kids about pet-care
Teaching kids about pet care
COVID-19 IMI2–Call 21
CARE launched to accelerate therapy development against COVID-19 and future coronavirus threats.
It is about saving lives Alexis Jaliquias feline blood bank
Veterinarian Alexis Jaliquias founded one of the first blood banks for cats in South America
Our Vision
At Boehringer Ingelheim, we have expanded our global research and development activities to tackle eye diseases, specifically those affecting the back of the eye.
Advances in vectored vaccines for poultry
Vaccine design technologies have made huge advances in recent years. One of the newer categories of vaccine, vectored vaccines, is overcoming challenges that conventional vaccines do not meet.
Three challenges shape future antiparasitic treatment
The three key challenges that will shape the future of antiparasitic treatment
The Research Process
The Research Process
COVID-19 and Mental Health
Co-creation with Communities
Making More Health has launched co-creation projects in Asia, Africa, Europe and other localities around the world with top social entrepreneurs.
Focus on Alliance Management
Stefan Walke, Global Head of Alliance Management, shares his perspectives on Alliance Management and its contribution to the development of successful long-term partnerships.
NeO - smart and sustainable vaccines
The reduction in the environmental impact of the new NeO vaccine packaging illustrates Boehringer Ingelheim’s drive for environmental responsibility.
Cattle well-being at farms’ core
From pain management to responsible use of antibiotics, Cattle First introduces a whole cow approach to look after health and productivity.
Our Contribution
Humanity is facing serious challenges. We believe we can always do more – for ourselves and for the generations to come.
“Rapid progress towards clinical candidates”
Boehringer Ingelheim forms a joint venture to create the next generation of antimicrobials.
Purevax®
Purevax® is the only fully adjuvant-free feline vaccine range.
The Angels Initiative
10 years of Making More Health
Looking behind the scenes of Afrika Kommt!
Looking behind the scenes of Afrika Kommt! with Sabine and Eunice. I in D&I audio interview with reflections on a program designed to build bridges.
Boehringer Ingelheim Academy
Find out more about our networking and educational initiative
Saving Stroke Patients around the world
Suffering a stroke is one of the most devastating medical emergencies that can happen to a person. Over 15 million people worldwide suffer a stroke every year.
COVID-19: Research Update
Boehringer Ingelheim stops treatment with experimental medication in study investigating benefits for severely ill patients with COVID-19
Code of Conduct
Our Code of Conduct sets the ethical standards that guides all our business activities. It´s about all of us. Each individual plays a vital role in bringing the Code of Conduct to live.
Idiopathic Pulmonary Fibrosis treatment launched in Egypt
Idiopathic Pulmonary Fibrosis treatment launched in Egypt